Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $7.6667.

A number of equities analysts recently issued reports on the stock. Guggenheim reissued a “buy” rating and issued a $14.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Tuesday, April 21st. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, February 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $8.00 price target on shares of Neumora Therapeutics in a research note on Tuesday, March 31st.

Neumora Therapeutics Stock Performance

Neumora Therapeutics stock opened at $1.84 on Friday. The company has a current ratio of 5.09, a quick ratio of 5.09 and a debt-to-equity ratio of 0.75. The firm has a 50-day moving average of $2.34 and a 200-day moving average of $2.38. The firm has a market cap of $340.92 million, a P/E ratio of -1.38 and a beta of 3.02. Neumora Therapeutics has a 1-year low of $0.65 and a 1-year high of $3.65.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Sell-side analysts expect that Neumora Therapeutics will post -0.98 EPS for the current year.

Insider Transactions at Neumora Therapeutics

In related news, insider Paul L. Berns sold 9,819 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the completion of the transaction, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This represents a 0.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 23,387 shares of company stock valued at $82,647 over the last ninety days. 26.94% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Legacy Private Trust Co. grew its holdings in Neumora Therapeutics by 35.7% in the fourth quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock worth $34,000 after purchasing an additional 5,000 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in Neumora Therapeutics by 10.7% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock worth $117,000 after purchasing an additional 6,233 shares during the period. Invesco Ltd. grew its holdings in Neumora Therapeutics by 6.8% in the second quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock worth $97,000 after purchasing an additional 8,383 shares during the period. Hsbc Holdings PLC purchased a new stake in Neumora Therapeutics in the fourth quarter worth about $27,000. Finally, Virtu Financial LLC purchased a new stake in Neumora Therapeutics in the third quarter worth about $31,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.